

# NICU Bedside Caregivers Sustain Process Improvement and Decrease Incidence of Bronchopulmonary Dysplasia in Infants < 30 Weeks Gestation

Sara J Mola MD, David J Annibale MD, Carol L Wagner MD,  
Thomas C Hulsey ScD, and Sarah N Taylor MD

**BACKGROUND:** The objective of this study was to investigate whether a respiratory care bundle, implemented through participation in the Vermont Oxford Network-sponsored Neonatal Intensive Care Quality Improvement Collaborative (NIC/Q 2005) and primarily dependent on bedside caregivers, resulted in sustained decrease in the incidence of bronchopulmonary dysplasia (BPD) in infants < 30 wk gestation. **METHODS:** A retrospective cohort study was conducted. Infants inborn between 23 wk and 29 wk + 6 d of gestation were included. Patients with congenital heart disease, significant congenital or lung anomalies, or death before intubation were excluded. Four time periods (T1–T4) were identified: T1: September 1, 2002 to August 31, 2004; T2: September 1, 2004 to August 31, 2006; T3: September 1, 2006 to August 31, 2008; T4: September 1, 2008 to August 31, 2010. **RESULTS:** A total of 1,050 infants were included in the study. BPD decreased significantly in T3 post-implementation of the respiratory bundle compared with T1 (29.9% vs 51.2%, respectively; adjusted odds ratio [aOR] = 0.06 [95% CI 0.03–0.13],  $P = < .001$ ). The decrease was not sustained into T4. There was a significant increase in the rate of BPD-free survival to discharge in T3 compared with T1 (53.1% vs 47%; aOR = 1.68 [95% CI 1.11–2.56],  $P = .01$ ) that was also not sustained. The rate of infants requiring O<sub>2</sub> at 28 d of life decreased significantly in T3 versus T1 (40.3% vs 69.9%, respectively; aOR = 0.12 [95% CI 0.07–0.20],  $P = < .001$ ). Increases in the rate of surfactant administration by 1 h of life and rate of caffeine use were observed in T4 versus T1, respectively. There was a significant decrease in median ventilator days and a significant increase in the median number of noninvasive CPAP days throughout the study period. **CONCLUSIONS:** In this study, implementation of a respiratory bundle managed primarily by nurses and respiratory therapists was successful in increasing the use of less invasive respiratory support in a consistent manner among very low birthweight infants at a single institution. However, this study and others have failed to show sustained improvement in the incidence of BPD despite sustained process change. *Key words:* bronchopulmonary dysplasia; very low birthweight; prematurity; mechanical ventilation; bedside caregiver; NICU. [Respir Care 2015;60(3):309–320. © 2015 Daedalus Enterprises]

## Introduction

With the advent of antenatal steroids, surfactant replacement therapy, and improved ventilatory and nutritional

strategies, there has been an increase in the survival of very low birthweight (VLBW) infants. However, little improvement in the incidence of bronchopulmonary dysplasia (BPD) has been appreciated.<sup>1</sup> Barotrauma, volutrauma,

---

Dr Mola is affiliated with the Department of Pediatrics, Division of Neonatology, University of Maryland School of Medicine, Baltimore, Maryland; Drs Annibale, Wagner, and Taylor are affiliated with the Department of Pediatrics, Division of Neonatal-Perinatal Medicine, Medical University of South Carolina, College of Medicine, Charleston, South Carolina; Dr Hulsey is affiliated with the Department of Pediatrics, Med-

---

ical University of South Carolina College of Medicine, Charleston, South Carolina.

The authors have disclosed no conflicts of interest.

Supplementary material related to this paper is available at <http://www.rcjournal.com>.

and oxygen toxicity have been recognized as significant contributors to the development of BPD in VLBW infants.<sup>2</sup> A reduction in the incidence of BPD in VLBW infants has been noted after the implementation of respiratory care quality improvement initiatives at other institutions.<sup>3-5</sup>

---

SEE THE RELATED EDITORIAL ON PAGE 469

---

From 2002–2003, a single 66-bed tertiary level neonatal intensive care center demonstrated a BPD rate in the highest quartile when compared with Vermont Oxford Network (VON) centers similar in size and acuity. In conjunction with the VON-sponsored Neonatal Intensive Care Quality Improvement Collaborative (NIC/Q 2005) with focus on respiratory care (Tender Lung Care [TLC]), a multidisciplinary group at this institution developed and implemented evidence-based improvements to increase noninvasive respiratory support and decrease oxygen exposure. The resulting respiratory care bundle was designed to integrate and standardize individual clinical interventions such as prophylactic surfactant administration, methylxanthine use, lower oxygen saturation targeting, and functional residual capacity preservation through post-extubation CPAP. The implementation of these interventions relied heavily upon bedside caregivers (ie, nurses and respiratory therapists) for consistency and sustainability, while physicians and neonatal nurse practitioners provided procedural and pharmacologic support.

The objective of this study was to investigate whether quality improvements implemented through participation in the TLC group of the VON-sponsored NIC/Q 2005 and primarily dependent on bedside caregiver modifications resulted in a sustained decrease in the incidence of BPD in infants < 30 wk gestation at a single tertiary care facility.

### Methods

The pathogenesis of BPD is multifactorial, and quality improvement efforts to decrease BPD typically use a bundle of interventions together. Each practice in the bundle may have varying levels of evidence, and the practices are often referred to as potentially better practices in neonatology.<sup>6</sup> In conjunction with the VON-sponsored NIC/Q TLC group (2005–2006), the participants from Medical University of South Carolina were charged with exploring the evidence for minimizing airway inflammation and oxygen toxicity. The group identified potentially better

### QUICK LOOK

#### Current knowledge

Advances in neonatal intensive care have resulted in an increase in the survival of very low birthweight (VLBW) infants. However, reductions in the incidence of bronchopulmonary dysplasia (BPD) have been small. Previous work has identified a reduction in the incidence of BPD in VLBW infants following the implementation of respiratory care quality improvement initiatives.

#### What this paper contributes to our knowledge

Implementation of a respiratory bundle in a single institution, which was primarily managed by respiratory therapists and nurses, increased the use of less invasive respiratory support in a consistent manner among VLBW infants. However, this intervention failed to show sustained reductions in the incidence of BPD.

practices after reviewing the respiratory care evidence available and comparing it to clinical practice: (1) early surfactant and extubation to CPAP to maintain functional residual capacity in preterm infants with respiratory distress syndrome and (2) oxygen saturation monitoring. Extensive education was provided to the nurses, respiratory therapists, neonatal nurse practitioners, physicians, and other ancillary staff regarding quality improvement, current evidence, and the implementation of each clinical change. An atmosphere of teamwork, consistency, and accountability was reinforced throughout the initiative.

#### Potentially Better Practice Implementation

A series of clinical practice changes were implemented as outlined in Figure 1. In early 2004, orders for lower target oxygen saturations of 88–92% and alarm limits of 85–95% were implemented.<sup>7-19</sup> Standardized  $F_{IO_2}$  blending of nasal cannula was also implemented during that time period. Bedside nursing staff and respiratory therapists were instrumental in the standardization of these clinical changes. In 2005, a respiratory therapist-driven ventilator management protocol was developed and implemented in an effort to integrate additional clinical practice changes (Tables 1 and 2). The evidence-based clinical improvements in this bundle included prophylactic surfactant administration, standardized methylxanthine use, and functional residual capacity preservation through post-extubation CPAP.<sup>20,21</sup> The evidence supporting surfactant prophylaxis in infants < 32 wk gestation at that time was reviewed in the Neonatal Cochrane Review by Soll and Morley<sup>20</sup> in 2000, with the primary outcome variable of BPD or death. The relative risk benefit was 0.85 (95% CI

---

Correspondence: Sara J Mola MD, Department of Pediatrics, Division of Neonatology, University of Maryland School of Medicine, 110 S Poca Street, 8th Floor, Baltimore, MD 21201. E-mail: smola@peds.umaryland.edu.

DOI: 10.4187/respcare.03235




Fig. 1. Clinical intervention over time. T1 = 2002–2004, T2 = 2004–2006, T3 = 2006–2008, T4 = 2008–2010. ETT = endotracheal tube.

Table 1. Standardized Ventilator Weaning Protocol

Clinical Parameter	Wean	Tolerate	Evaluate	Weaning Intervention
<b>Ventilator</b>				
Expiratory V <sub>T</sub> (mL/kg)	5–6	3–4	< 3 or > 6	Decrease ΔP (usually by decreasing PIP).
Mechanical ventilation (mL/kg/min)	240–400	160–240	< 160 or > 400	Decrease ΔP or breathing frequency, with goal of reducing expiratory V <sub>T</sub> first.
<b>Blood gas</b>				
pH	7.28–7.35	7.25–7.27	< 7.25 or > 7.35	If out-of-range pH is respiratory in origin (vs metabolic), adjust mechanical ventilation as above. If P <sub>aO<sub>2</sub></sub> or S <sub>pO<sub>2</sub></sub> is less than desired, wean rate rather than PIP.
P <sub>CO<sub>2</sub></sub> (mm Hg)	41–56	56–60	< 41 or > 60	Wean mechanical ventilation as above. If P <sub>aO<sub>2</sub></sub> or S <sub>pO<sub>2</sub></sub> is less than desired, wean rate rather than PIP.
P <sub>aO<sub>2</sub></sub> (mm Hg) (EGA 23–31 wk)	51–65	41–50	< 41 or > 65	Adjust by manipulating mean airway pressure (primarily by adjusting PEEP, but also with PIP or inspiratory time) or F <sub>IO<sub>2</sub></sub> .
P <sub>aO<sub>2</sub></sub> (mm Hg) (EGA 32–36 wk)	56–70	51–55	< 50 or > 70	In general, do not wean PEEP until F <sub>IO<sub>2</sub></sub> < 0.40.

V<sub>T</sub> = tidal volume  
 PIP = peak inspiratory pressure  
 EGA = estimated gestational age

0.76–0.95), and the number needed to treat to result in 2 fewer deaths and 5 fewer pneumothoraces was 100 neonates.<sup>20</sup> With this evidence, VON suggested a practice guideline to deliver surfactant prophylaxis to infants < 30 wk gestation. Survanta (beractant) was used across the study period, with 4 mL/kg administered in 2 aliquots with dosing every 6 h as needed via endotracheal tube for F<sub>IO<sub>2</sub></sub> requirements ≥ 0.30 and/or a mean airway pressure ≥ 7 cm H<sub>2</sub>O, for a total of 4 doses.

Caffeine dosing and implementation was based upon the Schmidt et al<sup>21</sup> study, which found extremely preterm infants randomized to receive caffeine in the first 7–10 d of life had a significantly reduced incidence of BPD. Infants ≤ 1,250 g or ≤ 30 wk gestation who were intubated, who were being weaned from positive-pressure ventilation, and for whom extubation was planned received a loading dose of 20 mg/kg caffeine citrate (Cafcit) intravenously, followed by a daily maintenance dose of 5 mg/kg.

Table 2. Suggested Escalation

Blood Gas Results	Possible Pathophysiology	Possible Responses With Ventilator
P <sub>aCO<sub>2</sub></sub> OK/low; P <sub>aO<sub>2</sub></sub> low	Atelectasis with $\dot{V}/\dot{Q}$ mismatch	Consider $\uparrow$ PEEP
P <sub>aCO<sub>2</sub></sub> OK/low; P <sub>aO<sub>2</sub></sub> OK/high	Overventilated	Consider $\downarrow$ PIP, OR $\downarrow$ PIP and PEEP (with $\downarrow$ $\Delta$ P), or $\downarrow$ rate
P <sub>aCO<sub>2</sub></sub> OK/high; P <sub>aO<sub>2</sub></sub> low	Atelectasis with resultant low V <sub>T</sub>	Consider $\uparrow$ PIP OR $\uparrow$ PIP and PEEP (with $\uparrow$ $\Delta$ P)
P <sub>aCO<sub>2</sub></sub> OK/high; P <sub>aO<sub>2</sub></sub> high	Inadequate minute ventilation with at least adequate FRC	Consider $\downarrow$ PEEP, $\uparrow$ rate, or $\uparrow$ PIP

$\dot{V}/\dot{Q}$  = ventilation/perfusion  
 PIP = peak inspiratory pressure  
 $\uparrow$  = increase  
 $\downarrow$  = decrease  
 V<sub>T</sub> = tidal volume  
 FRC = functional residual capacity

For continuing apnea, the daily dose could be increased to a maximum of 10 mg/kg caffeine citrate. This dosing was adjusted weekly for weight gain. Caffeine was continued until the infant was free of apnea requiring intervention for 7 d. Drug levels were not routinely monitored except for symptoms of caffeine toxicity (tachycardia, tachypnea, tremors, seizures, jitteriness, or vomiting). Routine dosing time was established in the morning so that babies could share a vial due to cost of caffeine citrate.

### Existing Evidence-Based Improvements

A number of potentially better practices identified as part of the TLC collaborative were already standard of care at this institution as a result of previous reviews of respiratory care literature. These included the use of vitamin A and suctioning without saline.<sup>22-32</sup> Methylxanthines were also used by some clinicians, but not in a standardized fashion before implementation of the protocol.<sup>33-36</sup>

### Study Design

After obtaining the hospital's institutional review board approval, we conducted a retrospective cohort study to investigate the incidence of BPD among VLBW infants before and after participation in a VON-sponsored NIC/Q focusing on noninvasive respiratory support. Four time periods (T1–T4) were identified: T1: September 1, 2002 to August 31, 2004; T2: September 1, 2004 to August 31, 2006; T3: September 1, 2006 to August 31, 2008; T4: September 1, 2008 to August 31, 2010. The majority of clinical interventions were implemented in T2 as noted in Figure 1. Baseline was defined as outcomes in T1. Outcomes in T3 were considered post-implementation outcomes, with outcomes in T4 representing sustainability of post-implementation outcomes.

De-identified data were obtained from a perinatal database that contains information on mother-baby pairs. Only inborn infants between 23 wk and 29 wk + 6 d of gesta-

tion were included in the study. Patients with congenital heart disease, significant congenital anomalies, or significant lung anomalies were excluded from the study. Patients were also excluded if death occurred without intubation, prophylactic surfactant, and mechanical ventilation, because the design of the study was to measure the effect of the respiratory bundle implementation.

### Clinical Definitions

The clinical definitions were consistent with those published by VON. Infants requiring supplemental oxygen at 36 wk postmenstrual age (PMA) were classified as having BPD. To account for those infants discharged from the hospital before 36 wk PMA, the definition of BPD was adjusted as follows: infants discharged from the hospital between 34 wk and 35 wk + 6 d PMA on supplemental oxygen were classified as requiring oxygen at 36 wk PMA and having BPD. Infants discharged to home without oxygen before 36 wk PMA or those in-patients not requiring supplemental oxygen at 36 wk PMA were categorized as not having BPD.

For the purposes of this study, prophylactic surfactant administration was defined as endotracheal administration by 1 h of life. Our clinical goal was endotracheal administration of surfactant by 15 min of life, followed by a period of brief mechanical ventilation. The infants were placed on pressure-limited ventilation in the delivery room for transport, and SIMV pressure-limited ventilation was continued upon admission to the NICU. Settings were weaned based upon the ventilator management protocol guidelines (Table 1). Subsequent surfactant dosing occurred at appropriate dosing intervals for mean airway pressures  $\geq 7$  cm H<sub>2</sub>O or F<sub>IO<sub>2</sub></sub> requirement  $\geq 0.30$ . Surfactant dosing and ventilator management were respiratory therapist-driven, and weaning was performed based upon minute ventilation and tidal volume parameters as outlined in the protocol guidelines (Table 1). Infants were extubated to CPAP via nasal prongs. Suggestions for escalation were

also provided with the protocol (Table 2). The protocol was developed based upon 2 prospective descriptive studies that present correlations between  $P_{aCO_2}$  and minute ventilation in preterm neonates.<sup>37,38</sup> At the time the workgroup convened, there were no studies addressing the use of ventilator weaning protocols for preterm neonates.

Lower oxygen saturation targeting of 88–92% was initially introduced in our NICU early in T2. This clinical change was further reinforced with the implementation of the ventilator management protocol that specified targeted oxygen saturations for titration of  $F_{IO_2}$  by bedside nursing staff and respiratory therapists.

### Primary Outcomes

Outcome measures were defined to be consistent with VON definitions as part of the TLC collaborative. Primary outcomes were defined as: rate of BPD (with adjusted definition as described under “Clinical Definitions”) analyzed as BPD-free survival because death and BPD are competing outcomes. Clinically important outcomes, such as rates of survival and supplemental oxygen requirement at 28 d, were also analyzed.

### Secondary Outcomes

Secondary outcome measures were: rate of prophylactic surfactant and methylxanthine use, days of CPAP therapy, days on ventilator, rate of postnatal steroid use, rate of discharge from the hospital on supplemental oxygen, length of hospital stay, rate of pneumothorax, patent ductus arteriosus (PDA), culture-proven sepsis, necrotizing enterocolitis, severe intraventricular hemorrhage or periventricular leukomalacia, and severe retinopathy of prematurity.

### Statistical Analysis

Data were tested for normal distribution. Non-normally distributed data were compared using Kruskal-Wallis test. Normally distributed data were compared by repeated measures analysis of variance. Other comparisons were made using chi-square, Fisher exact test,  $R \times C$  contingency tables, and logistic regression models. Significance was defined a priori as  $P < .05$ .

## Results

### Subject Demographics

A total of 1,050 infants were included in the study. The number of inborn infants  $< 30$  wk gestation admitted to the NICU was similar in all time periods. There was a noted decrease in the number of inborn 23–24 wk infants admitted in T4; however, this was not a statistically sig-

nificant trend when compared with the other defined time periods (Table 3). There was a significant difference in median birthweight and gestational age at delivery, with larger and more mature infants born in T4. This was expected, given the nonsignificant decrease in infants born at 23–24 wk PMA in T4. There were no differences in race, sex, or rate of small for gestational age infants between time periods.

As expected, there was a statistically significant increase in the rate of antenatal steroid therapy between time periods with 84% of mothers receiving therapy in T1 versus 92% in T4 ( $P = .007$ ). There was also a significant decrease in the rate of prenatal care between time periods (72% in T1 vs 64% in T4,  $P < .001$ ). There was no difference in the rate of chorioamnionitis, multiple births, mode of delivery, or rate of intrauterine growth restriction in the analysis (Table 3).

### Primary Outcomes

#### Rate of BPD

The rate of BPD as defined according to VON guidelines decreased significantly in T3 post-implementation of the respiratory bundle as compared with T1 (29.9% vs 51.2%, respectively; adjusted odds ratio [aOR] = 0.06 [95% CI 0.03–0.13],  $P = < .001$ ). In T4, there was a nonsignificant increase in the rate of BPD despite infants having a higher median gestational age and birthweight and fewer infants born at 23–24 wk gestation. There was not a significant difference between mortality rates in each time period (13.3% in T1 vs 10.5% in T3,  $P = 0.31$ ) and (10.5% in T3 vs 6.7% in T4,  $P = .12$ ) (Table 4, Fig. 2).

#### Rate of BPD-free Survival to Discharge

After controlling for gender, gestational age, birthweight, rate of prenatal care, antenatal steroids, postnatal steroids, and presence of PDA, there was a significant increase in the rate of BPD-free survival to discharge in T3 compared with T1 (53% vs 47%; aOR = 1.68 [95% CI 1.11–2.56],  $P = .01$ ). This demonstrates a marked improvement in the time period immediately following implementation of the respiratory care bundle. This improvement was not sustained, however, with the rate of BPD-free survival in T4 significantly decreasing to 41% compared with 53% in T3 (aOR = 0.57 [95% CI 0.38–0.88],  $P = .01$ ) (Table 4, Fig. 2).

#### Rate of $O_2$ at 28 d

The rate of infants requiring  $O_2$  at 28 d of life decreased significantly in T3 versus T1 (40.3% vs 69.9%, respec-

# NICU BEDSIDE CAREGIVERS DECREASE BPD

Table 3. Maternal and Infant Characteristics

Maternal and Infant Characteristics	T1 (n = 270)	T2 (n = 261)	T3 (n = 266)	T4 (n = 253)	P
Prenatal care (%)	71.8	82	69.6	64	< .001*
Antenatal steroids (%)	83.7	90.4	90.2	92.5	.007*
Chorioamnionitis (%)	7.4	9.6	12.8	9.9	.22
Preeclampsia/eclampsia (%)	20.7	28	19.6	24.5	.09
IUGR (%)	3.7	6.1	5.3	7.5	.29
Multiple births (%)	24.8	21.5	23.3	27.3	.47
Cesarean section (%)	64.8	70.9	67.7	66.8	.51
Gestational age (wk, median and IQR)	27.4 (26–28.6)	27.1 (25.4–28.5)	27.4 (25.6–28.5)	27.5 (26.2–29.1)	.05*
Birth weight (g, median and IQR)	995 (745–1165)	895 (710–1125)	922 (740–1150)	980 (785–1210)	.01*
Male (%)	54.8	57.1	51.5	51.4	.49
Black (%)	49.6	57.9	59.4	57.7	.09
SGA (%)	12.6	10.7	9	9	.49
23–24 wk gestational age (%)	15.6	16.5	14.3	9.1	.16
25–26 wk gestational age (%)	22.2	29.9	25.6	24.9	.16
27 wk gestational age (%)	20	14.6	18.1	21.7	.16
28 wk gestational age (%)	17.8	16.1	19.2	15.4	.16
29 wk gestational age (%)	24.4	23	22.9	28.9	.16

T1 = September 1, 2002 to August 31, 2004  
 T2 = September 1, 2004 to August 31, 2006  
 T3 = September 1, 2006 to August 31, 2008  
 T4 = September 1, 2008 to August 31, 2010  
 IUGR = rate of intrauterine growth restriction  
 IQR = interquartile range  
 SGA = small for gestational age  
 \* Statistical significance

Table 4. Primary Outcomes

Outcome	T1 (n = 270)	T2 (n = 261)	T3 (n = 266)	T4 (n = 253)	OR (95% CI)	
					T3 compared with T1§	T4 compared with T3†
BPD-free survival to discharge (%)	47	45.2	53.1	41.1	1.68 (1.11–2.56)*	0.57 (0.38–0.88)*
O <sub>2</sub> at 36 wk PMA or home on O <sub>2</sub> (%)‡	51.2	48	29.9	42.3	0.06 (0.03–0.13)*	1.55 (0.73–3.28)
O <sub>2</sub> at 28 d (%)	69.9	57.9	40.3	41.5	0.12 (0.07–0.20)*	1.03 (0.60–1.76)

T1 = September 1, 2002 to August 31, 2004  
 T2 = September 1, 2004 to August 31, 2006  
 T3 = September 1, 2006 to August 31, 2008  
 T4 = September 1, 2008 to August 31, 2010  
 OR = odds ratio  
 BPD = bronchopulmonary dysplasia  
 PMA = postmenstrual age  
 \* Statistical significance  
 † Odds ratios with 95% confidence intervals were calculated for T4 when compared to T3 controlling for gender, gestational age, birth weight, rate of prenatal care, antenatal steroids, postnatal steroids, and presence of PDA  
 ‡ Vermont Oxford Network definition of BPD  
 § Odds ratios with 95% confidence intervals were calculated for T3 when compared to T1 controlling for gender, gestational age, birth weight, rate of prenatal care, antenatal steroids, postnatal steroids, and presence of PDA

tively; aOR = 0.12 [95% CI 0.07–0.20],  $P = < .001$ ). There was no significant change in rate of O<sub>2</sub> requirement at 28 d between T3 and T4, implying a sustained decrease in the rate of VLBW infants requiring O<sub>2</sub> at 28 d post-implementation of the respiratory bundle when compared with rates pre-implementation in T1 (Table 4, Fig. 2).

### Secondary Outcomes

As expected, there was a significant trend toward improvement in the rate of prophylactic surfactant administration and methylxanthine use over the 8-y study period. In T1, 78.9% of infants received prophylactic surfactant




Fig. 2. A significant decrease in the rate of BPD was noted in T3 compared with T1 (29.9% vs 51.2%, respectively; adjusted odds ratio [aOR] = 0.06 [95% CI 0.03–0.13];  $P < .001$ ) as well as a decrease in O<sub>2</sub> requirement at 28 d (40.3% vs 69.9%, respectively; aOR = 0.119 [95% CI 0.07–0.20];  $P < .001$ ). Similarly, there was significant increase in the rate of BPD-free survival to discharge between T1 and T3 (53.1% vs 47%; aOR=1.68 [95% CI 1.11–2.56];  $P < .01$ ) that significantly decreased from T3 to T4. There was no significant difference in mortality rates for each time period. T1 = 2002–2004, T2 = 2004–2006, T3 = 2006–2008, T4 = 2008–2010. \* denotes significant change between T1 and T3. † denotes significant change between T3 and T4.

by 1 h of life versus 95.3% in T4 ( $P < .001$ ). The rate of caffeine use increased from 47.4% in T1 to 98% in T4 ( $P < .001$ ). Median ventilator days were significantly decreased by  $> 50\%$  from T1 to T4, with an expected subsequent increase in post-extubation CPAP days (Table 5). There was not a statistically significant difference between length of hospital stay or rates of pneumothorax, culture-proven sepsis, severe intraventricular hemorrhage or periventricular leukomalacia, and severe retinopathy of prematurity between time periods. There was an unexpected yet significant increase in the rate of PDA and postnatal steroid use in T4 when compared with T1 (21.9% vs 39.1%,  $P < .001$  and 12.6% vs 24.1%  $P < .001$ , respectively) (Table 5).

## Discussion

In this study, implementation of a respiratory bundle managed primarily by nurses and respiratory therapists was successful in implementing less invasive respiratory support and decreasing oxygen exposure in a consistent manner among VLBW infants at a single institution. However, this study failed to show sustained improvement in the incidence of BPD despite sustained process change. Significant clinical improvements have been sustained through 4 y post-implementation such as the significant

decrease in ventilator days and increase in CPAP days. Additionally, an increase in the percentage of infants receiving surfactant in the first postnatal hour and infants receiving caffeine therapy demonstrates continued utilization of these specific clinical interventions in the bundle.

A decreased BPD rate was appreciated in the first 2 y after implementation at our institution. Following logistic regression analysis controlling for the significant confounders including gender, gestational age, birthweight, rate of prenatal care, antenatal steroids, postnatal steroids, and presence of PDA, this significant decrease persisted. However, a nonsignificant, yet marked increase in the rate of BPD was noted in T4 when compared with T3. Additionally, when comparing survival without BPD at discharge by time period, a statistically significant increase was noted 2 y post-implementation that was not sustained. This raises concern that, despite a persistent decrease in ventilator days, an increase in CPAP, an increase in prophylactic surfactant delivery, and an increase in caffeine therapy, these evidence-based clinical improvements are not associated with improvement in long-term respiratory outcomes.

A unique characteristic of our intervention was reliance predominantly upon the bedside caregivers for implementation and maintenance. Only one other pediatric study has evaluated bedside caregiver-dependent quality improve-

## NICU BEDSIDE CAREGIVERS DECREASE BPD

Table 5. Secondary Outcomes

Outcome	T1 (n = 270)	T2 (n = 261)	T3 (n = 266)	T4 (n = 253)	P
Surfactant by 1 h of life (%)	78.9	90	93.2	95.3	< .001*
Caffeine therapy (%)	47.4	53.6	89.9	98	< .001*
Ventilator (d, median and IQR)	8.5 (2.0–32.0)	8.0 (2.0–33.0)	3.5 (1.0–23.0)	4.0 (1.0–23.0)	< .001*
CPAP (d, median and IQR)	4.0 (2.0–6.0)	4.0 (2.0–11.0)	8.0 (3.0–16.5)	8.0 (4.0–19.0)	< .001*
Postnatal steroids (%)	12.6	18.8	18.8	24.1	.009*
Length of stay (d, median and IQR)	54.5 (36.0–78.0)	53.0 (35.0–80.0)	52.0 (36.0–71.0)	55.0 (41.0–76)	.4
Home on O <sub>2</sub> (%)	44.4	50.2	44.8	54.2	.1
Pneumothorax (%)	3	5	6	4	.36
PDA (%)	21.9	31.4	24.8	39.1	< .001*
Early sepsis, culture proven (%)	1.1	1.9	1.9	0.8	.62
Severe IVH or PVL (%)	19.3	17.2	19.2	15.4	.62
Severe ROP (%)	6.7	5.4	4.5	5.1	.73

T1 = September 1, 2002 to August 31, 2004

T2 = September 1, 2004 to August 31, 2006

T3 = September 1, 2006 to August 31, 2008

T4 = September 1, 2008 to August 31, 2010

IQR = interquartile range

PDA = patent ductus arteriosus

IVH = intraventricular hemorrhage

PVL = periventricular leukomalacia

ROP = retinopathy of prematurity

\* Statistical significance

ments in respiratory care. Hermeto et al<sup>39</sup> reported the implementation of a respiratory therapist-driven ventilator protocol that was associated with shortened time to first extubation attempt, increased rate of successful extubation, and decreased duration under mechanical ventilation in infants < 1,250 g at birth. There was also a nonsignificant, yet appreciable decrease in rate of infants requiring oxygen at 28 d. The incidence of BPD, or oxygen requirement at 36 wk PMA, was not statistically different between groups. The study was not powered sufficiently to examine these respiratory outcomes. There are few pediatric articles describing pediatric ventilator protocols and outcomes.<sup>40,41</sup> This is in contrast to the adult literature, in which several randomized trials and prospective case series involving protocols directed by nursing, respiratory therapy, and computers have been associated with decreased times on mechanical ventilation and other improved outcomes.<sup>42–47</sup>

A 2004 study by Aly et al<sup>48</sup> demonstrated sustainable improvements in the rates of BPD and similar outcome variables such as a decrease in ventilator days and an increase in CPAP use after implementation of an early nasal CPAP management strategy. Other studies have evaluated respiratory care interventions but without a measurement of sustainability. Birenbaum and colleagues<sup>5</sup> demonstrated successful process outcomes such as increased use of the T-piece resuscitator in the delivery room, increased use of nasal CPAP in the delivery room, and decreased time on mechanical ventilation at a single institution. They found a reduction in the incidence of BPD from

46.5% in 2002 to 20.5% in 2005, with an overall relative risk reduction of 55.8% following implementation of quality improvements. However, they did not evaluate the ability to sustain these clinical processes or results.

Likewise, the NIC/Q Breathsavers group in 2002 noted improvements in process outcomes including decreased time on mechanical ventilation, time to initial surfactant administration, and increased CPAP use following identification and implementation of 13 potentially better practices among 18 participating centers. There was also a noted 27% overall reduction in the incidence of BPD over a 2-y period following implementation of clinical modifications.<sup>4,49</sup> However, the participating centers aimed at reducing BPD rates demonstrated markedly varying results. Some NICUs with low baseline rates of BPD demonstrated paradoxical increases in BPD rates.<sup>6</sup> Payne et al<sup>4</sup> described the possibility of the Hawthorne effect, or the improvement in performance that is seen when performance receives extra scrutiny, that may have contributed to improved outcomes in their study. Participants in these collaboratives are also self-selected and highly motivated individuals, and these factors may well have contributed to the improved rates of BPD initially observed with the Breathsavers group, as well as with our study.<sup>6</sup> It is a possibility that our bedside caregivers experienced “bundle fatigue” with time, which may have contributed to the increase in BPD rates observed in T4 in our study.

Another monitor of respiratory outcomes is survival without BPD, or BPD-free survival. In a cluster-randomized trial that involved 17 centers of the National Institute of



Child Health and Human Development (NICHD) Neonatal Research Network, benchmarking and multimodal quality improvement were successful in changing practice such as reducing oxygen exposure and mechanical ventilation duration, but did not reduce the rate of survival free of BPD.<sup>50</sup> Similarly, Horbar et al<sup>51</sup> did not demonstrate a significant decrease in the combined outcome of death or O<sub>2</sub> supplementation at 36 wk despite significant measurable process change in the 4 participating NICUs. These findings are consistent with the results of our observational study that, despite successful, sustained implementation of evidence-based quality improvements in respiratory care emphasizing noninvasive respiratory support, long-term outcomes such as BPD-free survival may not sustain positive change.

What could account for the discrepancy of improved respiratory care with less oxygen need at 28 d but with persistence in prevalence of BPD? BPD is known to be a complex, multifactorial disease process, illustrated by the finding that some VLBW infants demonstrate little to no initial lung disease, but subsequently develop BPD.<sup>52</sup> Barotrauma and volutrauma by mechanical ventilation, combined with atelectotrauma, and exposure to oxygen toxicity contribute to inflammatory reactions that persist past the immediate neonatal period and contribute to the development of BPD.<sup>53-56</sup>

At the time of this study, there was only one T-piece resuscitator available in the NICU for bedside resuscitation or unintended extubation. This was often reserved for the most immature or critically-ill infants, or infants with air leak. Otherwise, a neonatal manual resuscitation bag would have been utilized in those clinical situations. There were also no F<sub>IO<sub>2</sub></sub> blenders at bedside at the time of the study. T-piece resuscitators and blended F<sub>IO<sub>2</sub></sub> were present and utilized for all VLBW deliveries in the delivery room. One could speculate that respiratory care administered at the bedside with bag-valve-mask and oxygen exposure may be a significant contributor to the development of BPD. As animal studies have demonstrated, just 6 large tidal volume breaths had potential to cause severe preterm lamb lung injury.<sup>57</sup> The subsequent inflammatory response that ensues may contribute to a protracted course of lung injury. Unfortunately there was no standardized collection of data surrounding unintended extubations or number of positive-pressure events at bedside in the NICU at the time of the study. The lack of this pertinent clinical information is a limitation to our study, given the retrospective study design.

There has also been emerging evidence to suggest that initiation of CPAP for extremely preterm infants is an acceptable alternative to prophylactic surfactant administration. The SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network randomized > 1,300 extremely low birthweight neonates to

either CPAP or intubation, prophylactic surfactant within 1 h of life followed by a brief period of ventilation. The primary outcome of death or BPD was no different between the groups. However, infants who received CPAP treatment, as compared with infants who received surfactant treatment, less frequently required intubation or postnatal corticosteroids for BPD ( $P < .001$ ), required fewer days of mechanical ventilation ( $P = .03$ ), and were more likely to be alive and free from the need for mechanical ventilation by day 7 ( $P = .01$ ). The rates of other adverse neonatal outcomes did not differ significantly between the 2 groups.<sup>58</sup> The design of our bundle incorporates a brief period of mechanical ventilation and a weaning protocol similar to the prophylactic surfactant arm of this study. Any positive-pressure ventilation delivered to preterm infants may contribute to a cascade of inflammatory reactions that may subsequently contribute to the development of BPD.<sup>57</sup> Given the SUPPORT trial outcome, early use of noninvasive support such as CPAP without intubation and ventilation may have also contributed to the sustained success documented by Aly et al<sup>48</sup> in decreasing the incidence of BPD at their institution.

Another reason for the discrepancy between improved respiratory techniques and sustained outcome may be that definitions of BPD lack a rigorous, consistent approach to integrating oxygen delivery into the diagnosis. Walsh and colleagues<sup>59</sup> demonstrated that the development and implementation of a rigorous physiologic definition of BPD that included a room air challenge for infants receiving < 30% effective oxygen resulted in a mean reduction of 10% in rates of BPD. At the time this study was conducted, no uniform guidelines for nasal cannula weaning or for a room air challenge at 36 wk PMA were in place at our institution. Additionally, some clinicians implement oxygen therapy for preterm infants with poor oral feeding technique or apnea and desaturation events during feeds. Infants may be discharged to home on oxygen solely to be utilized during feeds and are misdiagnosed as having BPD without meeting true physiologic criteria. Despite little evidence to support this practice, it continues to occur and may contribute to the discrepancy noted between O<sub>2</sub> requirement at 28 d and 36 wk PMA at this institution.

An unexpected outcome in our study was a nonsignificant, yet marked increase in the use of postnatal steroids during the study period. However, despite the rise in postnatal steroid use, the rate of BPD continued to increase from T3 to T4 after controlling for this variable. Since the American Academy of Pediatrics policy statement in 2002 stating that routine dexamethasone therapy could not be recommended without further study and long-term follow-up, postnatal steroid use in preterm infants has decreased.<sup>60</sup> There have been 2 randomized controlled trials published since the 2002 policy statement demonstrating increased successful extubation with later, low-dose dexamethasone

compared with control. Neither study was powered to evaluate the effect of the treatment on survival without BPD.<sup>61,62</sup> The increase in steroid use at our institution noted during this study may be in part to the adoption of practice to administer later, low-dose dexamethasone to facilitate extubation in chronically ventilated infants. This has been noted as a potential confounder as well as limitation in this retrospective study design.

The increased rate of PDA observed across the study period was also an unexpected outcome. The increase in rate of PDA may be explained by a few clinical factors. There was practice variation among clinicians regarding PDA management. Data regarding management strategies were not collected, and this is a limitation to the study. The practice to give prophylactic indomethacin to neonates < 1,000 g at birth was routine among clinicians early in the study period. However, this practice was discontinued in T4. This time point was not collected and not accounted for in the statistical analysis. There was also practice variation among obstetricians regarding agents used for tocolysis of preterm labor. Indomethacin was frequently used as a tocolytic agent during this time period and could also contribute to the increased rates of PDA if fewer women received prenatal care, and therefore indomethacin exposure. The data regarding use of indomethacin for tocolysis among the obstetricians were not collected and accounted for in the statistical analysis and are therefore another limitation to the study.

There are few data supporting the role of PDA in the development of BPD. To date, there is only one randomized controlled trial, which was performed in the 1970s, that has examined the pulmonary effects of prolonged exposure to PDA in extremely premature infants requiring mechanical ventilation. The investigators compared the effects of ligating the PDA versus allowing PDA to persist and found that ligation decreased the need for prolonged mechanical ventilation.<sup>63</sup> Studies have suggested that the mean airway pressure and  $F_{IO_2}$  needed to overcome PDA-induced changes in pulmonary compliance may contribute to the development of BPD; however, there is little evidence from controlled clinical trials.<sup>63-65</sup> An additional limitation of the study is the lack of data such as mean airway pressures, mean CPAP levels, and  $F_{IO_2}$  requirements. In addition, because it was a before-and-after study, the possibility exists that other unrecognized changes were taking place concurrently with the study.

### Conclusions

In this study, implementation of a respiratory bundle managed primarily by nurses and respiratory therapists was successful in increasing the use of less invasive respiratory support in a consistent manner among VLBW infants at a single institution. In doing so, the rate of BPD

was improved in the 2 y after implementation of the protocol. This demonstrates that improvement in complex outcomes such as BPD may be achieved through quality improvement methodology involving primarily bedside caregivers. However, this study and several others have failed to show sustainability in improvement of this complex respiratory outcome despite sustained process change. This warrants further study into the pathogenesis of BPD and the optimal team factors to determine the best practices for decreasing BPD rates in a sustainable fashion.

### REFERENCES

1. Jobe AH. Mechanisms to explain surfactant responses. *Biol Neonate* 2006;89(4):298-302.
2. Varughese M, Patole S, Shama A, Whitehall J. Permissive hypercapnia in neonates: the case of the good, the bad, and the ugly. *Pediatr Pulmonol* 2002;33(1):56-64.
3. Clark RH, Gerstmann DR, Jobe AH, Moffitt ST, Slutsky AS, Yoder BA. Lung injury in neonates: causes, strategies for prevention, and long-term consequences. 2001;139(4):478-486.
4. Payne NR, LaCorte M, Karna P, Chen S, Finkelstein M, Goldsmith JP, et al. Reduction of bronchopulmonary dysplasia after participation in the Breathsavers Group of the Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative. *Pediatrics* 2006;118 (Suppl 2):S73-S77.
5. Birenbaum HJ, Dentry A, Cirelli J, Helou S, Pane MA, Starr K, et al. Reduction in the incidence of chronic lung disease in very low birth weight infants: results of a quality improvement process in a tertiary level neonatal intensive care unit. *Pediatrics* 2009;123(1):44-50.
6. Pfister RH, Goldsmith JP. Quality improvement in respiratory care: decreasing bronchopulmonary dysplasia. *Clin Perinatol* 2010;37(1): 273-293.
7. Tin W, Milligan DW, Pennfather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. *Arch Dis Child Fetal Neonatal Ed* 2001;84(2):F106-F110.
8. Chow LC, Wright KW, Sola A, CSMC Oxygen Administration Study Group. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? *Pediatrics* 2003;111(2):339-345.
9. Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity and pulse oximetry: a national survey of recent practices. *J Perinatol* 2004;24(3):164-168.
10. Rabi Y, Rabi D, Yee W. Room air resuscitation of the depressed newborn: a systematic review and meta-analysis. *Resuscitation* 2007; 72(3):353-363.
11. Silvers KM, Gibson AT, Russell JM, Powers HJ. Antioxidant activity, packed cell transfusions, and outcome in premature infants. *Arch Dis Child Fetal Neonatal Ed* 1998;78(3):F214-F219.
12. Saugstad OD. Bronchopulmonary dysplasia and oxidative stress: are we closer to an understanding of the pathogenesis of BPD? *Acta Paediatr* 1997;86(12):1277-1282.
13. Davis JM. Role of oxidant injury in the pathogenesis of neonatal lung disease. *Acta Paediatr Suppl* 2002;91(437):23-25.
14. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2001;163(7):1723-1729.
15. Wright KW, Sami D, Thompson L, Ramanathan R, Joseph R, Farzavandi S. A physiologic reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity. *Trans Am Ophthalmol Soc* 2006;104:78-84.
16. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. *N Engl J Med* 2003;349(10):959-967.

17. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. *Pediatrics* 2000;105(2):295-310.
18. Gaynon MW, Stevenson DK. What can we learn from STOP-ROP and earlier studies? *Pediatrics* 2000;105(2):420-421.
19. Hay WW Jr, Bell EF. Oxygen therapy, oxygen toxicity, and the STOP-ROP trial. *Pediatrics* 2000;105(2):424-425.
20. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants. *Cochrane Database Syst Rev* 2000;(2):CD000510.
21. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. *N Engl J Med* 2006;354(20):2112-2121.
22. Hagler DA, Traver GA. Endotracheal saline and suction catheters: sources of lower airway contamination. *Am J Crit Care* 1994;3(6):444-447.
23. Ridling DA, Martin LD, Bratton SL. Endotracheal suctioning with or without instillation of isotonic sodium chloride solution in critically ill children. *Am J Crit Care* 2003;12(3):212-219.
24. Beeram MR, Dhanireddy R. Effects of saline instillation during tracheal suction on lung mechanics in newborn infants. *J Perinatol* 1992;12(2):120-123.
25. Kinloch D. Instillation of normal saline during endotracheal suctioning: effects on mixed venous oxygen saturation. 1999; *Am J Crit Care* 8(4):231-240; quiz 241-232.
26. Shorten DR, Byrne PJ, Jones RL. Infant responses to saline instillations and endotracheal suctioning. *J Obstet Gynecol Neonatal Nursing* 1991;20(6):464-469.
27. Bostick J, Wendelgass ST. Normal saline instillation as part of the suctioning procedure: effects on PaO<sub>2</sub> and amount of secretions. *Heart Lung J Crit Care* 1987;16(5):532-537.
28. Shenai JP, Chytil F, Jhaveri A, Stahlman MT. Plasma vitamin A and retinol-binding protein in premature and term neonates. *J Pediatr* 1981;99(2):302-305.
29. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. *Cochrane Database Syst Rev* 2007;(4):CD000501.
30. Ambalavanan N, Wu TJ, Tyson JE, Kennedy KA, Roane C, Carlo WA. A comparison of three vitamin A dosing regimens in extremely-low-birth-weight infants. *J Pediatr* 2003;142(6):656-661.
31. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. *N Engl J Med* 1999;340(25):1962-1968.
32. Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, et al. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. *J Pediatr* 2002;141(3):370-374.
33. Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. *Cochrane Database Syst Rev* 2001;(3):CD000140.
34. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for extubation in preterm infants. *Cochrane Database Syst Rev* 2003;(1):CD000139.
35. Steer PA, Flenady VJ, Shearman A, Lee TC, Tudehope DI, Charles BG. Periextubation caffeine in preterm neonates: a randomized dose response trial. *J Paediatr Child Health* 2003;39(7):511-515.
36. Steer P, Flenady V, Shearman A, Charles B, Gray PH, Henderson-Smart D, et al. High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial. *Arch Dis Child Fetal Neonatal Ed* 2004;89(6):F499-503.
37. Mathur NB, Bhatia V. Effect of stepwise reduction in minute ventilation on PaCO<sub>2</sub> in ventilated newborns. *Indian Pediatr* 2004;41(8):779-785.
38. Davies MW, Kecskes ZB, Berrington J. Determining the ventilatory volumes required to ventilate low birth weight infants with respiratory distress syndrome: prediction of arterial carbon dioxide using minute volumes. *Biol Neonate* 2002;82(4):233-237.
39. Hermeto F, Bottino MN, Vaillancourt K, Sant'Anna GM. Implementation of a respiratory therapist-driven protocol for neonatal ventilation: impact on the premature population. *Pediatrics* 2009;123(5):e907-e916.
40. Randolph AG, Wypij D, Venkataraman ST, Hanson JH, Gedeit RG, Meert KL, et al. Effect of mechanical ventilator weaning protocols on respiratory outcomes in infants and children: a randomized controlled trial. *J Am Med Assoc* 2002;288(20):2561-2568.
41. Schultz TR, Lin RJ, Watzman HM, Durning SM, Hales R, Woodson A, et al. Weaning children from mechanical ventilation: a prospective randomized trial of protocol-directed versus physician-directed weaning. *Respir Care* 2001;46(8):772-782.
42. Ely EW, Meade MO, Haponik EF, Kollef MH, Cook DJ, Guyatt GH, et al. Mechanical ventilator weaning protocols driven by nonphysician health-care professionals: evidence-based clinical practice guidelines. *Chest* 2001;120(6 Suppl):454S-463S.
43. Ely EW, Baker AM, Dunagan DP, Burke HL, Smith AC, Kelly PT, et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. *N Engl J Med* 1996;335(25):1864-1869.
44. Kollef MH, Shapiro SD, Silver P, St John RE, Prentice D, Sauer S, et al. A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation. *Crit Care Med* 1997;25(4):567-574.
45. Marelich GP, Murin S, Battistella F, Inciardi J, Vierra T, Roby M. Protocol weaning of mechanical ventilation in medical and surgical patients by respiratory care practitioners and nurses: effect on weaning time and incidence of ventilator-associated pneumonia. *Chest* 2000;118(2):459-467.
46. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. *Lancet* 2008;371(9607):126-134.
47. Girard TD, Ely EW. Protocol-driven ventilator weaning: reviewing the evidence. *Clin Chest Med* 2008;29(2):241-252, v.
48. Aly H, Milner JD, Patel K, El-Mohandes AA. Does the experience with the use of nasal continuous positive airway pressure improve over time in extremely low birth weight infants? *Pediatrics* 2004;114(3):697-702.
49. Payne NR, LaCorte M, Sun S, Karna P, Lewis-Hunstiger M, Goldsmith JP, et al. Evaluation and development of potentially better practices to reduce bronchopulmonary dysplasia in very low birth weight infants. *Pediatrics* 2006;118 Suppl 2:S65-S72.
50. Walsh M, Lupton A, Kazzi SN, Engle WA, Yao Q, Rasmussen M, et al. A cluster-randomized trial of benchmarking and multimodal quality improvement to improve rates of survival free of bronchopulmonary dysplasia for infants with birth weights of less than 1250 grams. *Pediatrics* 2007;119(5):876-890.
51. Horbar JD, Rogowski J, Plsek PE, Delmore P, Edwards WH, Hocker J, et al. Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network. *Pediatrics* 2001;107(1):14-22.
52. Bancalari E. Bronchopulmonary dysplasia: old problem, new presentation. *J Pediatr (Rio J)* 2006;82(1):2-3.
53. Pierce MR, Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. *Pediatr Pulmonol* 1995;19(6):371-378.

## NICU BEDSIDE CAREGIVERS DECREASE BPD

54. Groneck P, Speer CP. Inflammatory mediators and bronchopulmonary dysplasia. *Arch Dis Child Fetal Neonatal Ed* 1995;73(1): F1-3.
55. Ozdemir A, Brown MA, Morgan WJ. Markers and mediators of inflammation in neonatal lung disease. *Pediatr Pulmonol* 1997;23(4): 292-306.
56. Munshi UK, Niu JO, Siddiq MM, Parton LA. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. *Pediatr Pulmonol* 1997;24(5):331-336.
57. Bjorklund LJ, Ingimarsson J, Curstedt T, John J, Robertson B, Werner O, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. *Pediatr Res* 1997;42(3):348-355.
58. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, et al. Early CPAP versus surfactant in extremely preterm infants. *N Engl J Med* 2010;362(21):1970-1979.
59. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. *Pediatrics* 2004;114(5):1305-1311.
60. Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee SK, Ohlsson A. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. *Pediatrics* 2006;118(5):e1328-1335.
61. Walther FJ, Findlay RD, Durand M. Adrenal suppression and extubation rate after moderately early low-dose dexamethasone therapy in very preterm infants. *Early Hum Dev* 2003;74(1):37-45.
62. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB, DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. *Pediatrics* 2006;117(1): 75-83.
63. Cotton RB, Stahlman MT, Bender HW, Graham TP, Catterton WZ, Kovar I. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. *J Pediatr* 1978;93(4):647-651.
64. Brown ER. Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus. *J Pediatr* 1979;95(5 Pt 2):865-866.
65. Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. *J Pediatr* 1996; 128(5 Pt 1):601-607.

This article is approved for Continuing Respiratory Care Education credit. For information and to obtain your CRCE (free to AARC members) visit [www.rcjournal.com](http://www.rcjournal.com)

